Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas

Inclusion Criteria

• •Patients with refractory or relapsed aggressive non-Hodgkin's Lymphoma. The definition of refractory includes patients who either did not respond to prior therapy or those whose best response was a PR after at least 4 courses of chemotherapy. Aggressive histologies include follicular large cell, diffuse large cell, peripheral T cell, transformed lymphomas, Lymphoblastic lymphomas, Burkitt and Burkitt like lymphomas.
• •Histologic or cytological confirmation of refractory or relapsed aggressive non-Hodgkin's Lymphoma is desirable but not mandatory and will be left to the discretion of the investigator.
• •Must have measurable or evaluable disease.
• •No more than 4 previous regimens of chemotherapy will be allowed, including stem cell or bone marrow transplant.
• •Patients must be more than 18 years old.
• •No evidence of grade 3 or more neurosensory or neuromotor dysfunction (see appendix- toxicity criteria)
• •Written Consent
• •Those patients who have previously received a platinum or nucleoside analogue-containing regimen are eligible.
• •Patients who are candidates for stem cell or marrow transplant will be included